- Home
- RLYB vs CNTB Comparison
RLYB vs CNTB Comparison
Compare RLYB & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- CNTB
- Stock Information
- Founded
- RLYB 2018
- CNTB 2012
- Country
- RLYB United States
- CNTB United States
- Employees
- RLYB N/A
- CNTB N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- CNTB Health Care
- Exchange
- RLYB Nasdaq
- CNTB Nasdaq
- Market Cap
- RLYB 14.4M
- CNTB 54.4M
- IPO Year
- RLYB 2021
- CNTB 2021
- Fundamental
- Price
- RLYB $0.41
- CNTB $1.53
- Analyst Decision
- RLYB Hold
- CNTB Strong Buy
- Analyst Count
- RLYB 3
- CNTB 2
- Target Price
- RLYB $15.00
- CNTB $7.50
- AVG Volume (30 Days)
- RLYB 8.1M
- CNTB 156.2K
- Earning Date
- RLYB 08-07-2025
- CNTB 09-04-2025
- Dividend Yield
- RLYB N/A
- CNTB N/A
- EPS Growth
- RLYB N/A
- CNTB N/A
- EPS
- RLYB N/A
- CNTB N/A
- Revenue
- RLYB $848,000.00
- CNTB $26,033,000.00
- Revenue This Year
- RLYB N/A
- CNTB N/A
- Revenue Next Year
- RLYB N/A
- CNTB N/A
- P/E Ratio
- RLYB N/A
- CNTB N/A
- Revenue Growth
- RLYB N/A
- CNTB N/A
- 52 Week Low
- RLYB $0.22
- CNTB $0.51
- 52 Week High
- RLYB $1.54
- CNTB $1.60
- Technical
- Relative Strength Index (RSI)
- RLYB 55.26
- CNTB 66.20
- Support Level
- RLYB $0.32
- CNTB $1.05
- Resistance Level
- RLYB $0.61
- CNTB $1.20
- Average True Range (ATR)
- RLYB 0.05
- CNTB 0.09
- MACD
- RLYB 0.01
- CNTB 0.01
- Stochastic Oscillator
- RLYB 34.82
- CNTB 82.76
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.